In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates

Tato, Marta; Pedrosa, Elia Gómez-G. de la; Cantón, Rafael; Gómez-García, I.; Fortün, Jesús; Martín‐Dávila, Pilar; Baquero, Fernando; Gómez-Mampaso, E

doi:10.1016/j.ijantimicag.2006.02.011

Cited by 52 publications

(32 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro and pharmacogenetic data suggest that oxazolidinones could be useful in management of mycobacterial infection, including MDR TB (29)(30)(31)(32). However, clinical experience with the use of linezolid in the management of mycobacterial infections has been mainly restricted to case reports in nontuberculous mycobacterial diseases (33)(34)(35) and to a few case reports on patients with MDR TB (28,36,37).…”

Section: Discussionmentioning

confidence: 99%

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Eker¹,

Ortmann²,

Migliori³

et al. 2008

Emerg. Infect. Dis.

125

View full text Add to dashboard Cite

We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in [2004][2005][2006]. In 177 (4%) of 4,557 culture-positive TB cases, Mycobacterium tuberculosis isolates were identifi ed as MDR TB; an additional 7 (0.15%) met criteria for XDR TB. Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union. In patients with XDR TB, hospitalization was longer (mean ± SD 202 ± 130 vs. 123 ± 81 days; p = 0.015) and resistance to all fi rst-line drugs was more frequent (36% vs. 86%; p = 0.013) than in patients with MDR TB. Seventyfour (40%) of these 184 patients received treatment with linezolid. Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a defi nitive outcome (n = 125; 89% for MDR TB and 80% for XDR TB). Extensive drug susceptibility testing and availability of second-and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR and XDR TB.

show abstract

Section: Discussionmentioning

confidence: 99%

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Eker¹,

Ortmann²,

Migliori³

et al. 2008

Emerg. Infect. Dis.

125

View full text Add to dashboard Cite

show abstract

“…In vitro and pharmacological data suggest that linezolid, an oxazolidinone antibiotic, could be efficacious in treating mycobacterial infections, including MDR-TB [16][17][18][19][20][21].…”

mentioning

confidence: 99%

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

Sotgiu¹,

Centis²,

et al. 2012

View full text Add to dashboard Cite

Linezolid is used off-label to treat multidrug-resistant tuberculosis (MDR-TB) in absence of systematic evidence. We performed a systematic review and meta-analysis on efficacy, safety and tolerability of linezolid-containing regimes based on individual data analysis.12 studies (11 countries from three continents) reporting complete information on safety, tolerability, efficacy of linezolid-containing regimes in treating MDR-TB cases were identified based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Metaanalysis was performed using the individual data of 121 patients with a definite treatment outcome (cure, completion, death or failure).Most MDR-TB cases achieved sputum smear (86 (92.5%) out of 93) and culture (100 (93.5%) out of 107) conversion after treatment with individualised regimens containing linezolid (median (inter-quartile range) times for smear and culture conversions were 43.5 (21-90) and 61 (29-119) days, respectively) and 99 (81.8%) out of 121 patients were successfully treated. No significant differences were detected in the subgroup efficacy analysis (daily linezolid dosage f600 mg versus .600 mg). Adverse events were observed in 63 (58.9%) out of 107 patients, of which 54 (68.4%) out of 79 were major adverse events that included anaemia (38.1%), peripheral neuropathy (47.1%), gastro-intestinal disorders (16.7%), optic neuritis (13.2%) and thrombocytopenia (11.8%). The proportion of adverse events was significantly higher when the linezolid daily dosage exceeded 600 mg.The study results suggest an excellent efficacy but also the necessity of caution in the prescription of linezolid.

show abstract

“…It exhibits no cross-resistance with other anti-TB drugs (1,2,5,11,15,17). Given the long doubling time of Mycobacterium tuberculosis populations and the high cost, myelosuppression, and neurotoxicity of linezolid, some clinicians have tried administering one-half of the usual dose (600 mg once daily) (12).…”

mentioning

confidence: 99%

Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis

McGee

Dietze

Hadad

et al. 2009

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Nineteen adults with pulmonary tuberculosis received linezolid (600 mg) once or twice daily in an early bactericidal activity trial. A one-compartment population model produced median values for the absorption rate constant, volume of distribution, and elimination rate constant of 1.5 h ؊1 , 29.6 liters, and 0.25 h ؊1 (once daily) and 2.7 h ؊1 , 32.1 liters, and 0.15 h ؊1 (twice daily). Linezolid administered twice daily produced higher values for free drug area under the concentration-time curve

show abstract

In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates

Cited by 52 publications

References 21 publications

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis

Contact Info

Product

Resources

About